Past, present and future strategies of immunotherapy in gynecological malignancies

Current Molecular Medicine

Volumn 13, Issue 4, 2013, Pages 648-669

  Bellati, F ^a,b   Napoletano, C ^a   Ruscito, I ^b   Visconti, V ^a   Antonilli, M ^b   Gasparri, M L ^b   Zizzari, I G ^a   Rahimi, H ^a   Palaia, I ^b   Rughetti, A ^a   Panici, P Benedetti ^b   Nuti, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti idiotypic antibody; Cancer vaccine; Cervical cancer; Dendritic cells; Gynecological cancer; Immunotherapy; Lymphocytes; Ovarian cancer

Indexed keywords

ABAGOVOMAB; ANTIIDIOTYPIC ANTIBODY; BETA INTERFERON; CARBOHYDRATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NY ESO 1 ANTIGEN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN E7; THERATOPE; VIRUS DNA; VIRUS VECTOR;

ANEMIA; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; COLON PERFORATION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; GYNECOLOGIC CANCER; HUMAN; IMMUNOGENICITY; LYMPHOCYTE; MELANOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); T LYMPHOCYTE; UTERINE CERVIX CANCER; UTERUS SARCOMA; VACCINATION;

CANCER VACCINES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY;

EID: 84876699831     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313040014     Document Type: Article

References (108)

1. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 900-901.
2. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 11: 187-193.
3. Rustin GJ, Quinn M, Thigpen T, et al. RE: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Nat Cancer Inst 2004; 96: 487-8.
4. Bellati F, Napoletano C, Gasparri ML, et al. Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm. J Clin Oncol 2010; 28: 471-472.
5. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
6. Napoletano C, Bellati F, Landi R, et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010; 14: 2748-2759.
7. Li D, Xue M, Wang C, et al. Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickens. Clin Vaccine Immunol 2011; 18: 1497-1502.
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
9. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 1: 161-192.
10. Bellati F, Napoletano C, Gasparri ML, et al. Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol 2012; 83: 35-46.
11. Bellati F, Napoletano C, Gasparri ML, et al. Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol 2011; 2011: 890758.
12. Bellati F, Visconti V, Napoletano C, et al. Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets 2009; 9: 541-565.
13. Salazar LG, Disis ML. Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol 2005; 23: 7397-7398.
14. Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5: 1289-1297.
15. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-2632.
16. Ohno S, Takano F, Ohta Y, et al. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination. Anticancer Res 2011; 31: 2447-2452.
17. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 12837-12842.
18. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14: 2740-2748.
19. Odunsi K, Matsuzaki J, Karbach J, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012; 109: 5797-5802.
20. Chianese-Bullock KA, Irvin WP Jr, Petroni GR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31: 420-430.
21. Kaumaya PT, Foy KC, Garrett J, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009; 27: 5270-5277.
22. Li D, Hua S, Fan Y, et al. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice. Immunol Lett 2011; 30: 124-128.
23. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14: 3060-3069.
24. Mohebtash M, Tsang KY, Madan RA, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17: 7164-7173.
25. Baxevanis CN. Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. Expert Rev Vaccines 2012; 11: 275-277.
26. Sandmaier BM, Oparin DV, Holmberg LA, et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22: 54-66.
27. Sabbatini PJ, Ragupathi G, Hood C, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007; 13: 4170-4177.
28. Sabbatini PJ, Kudryashov V, Ragupathi G, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87: 79-85.
29. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125: 373-389.
30. Chatterjee MB, Foon KA, Köhler H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 1994; 38: 75-82.
31. Foon KA, Oseroff AR, Vaickus L, et al. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1995; 1: 1285-1294.
32. Herlyn D, Zaloudik J, Somasundaram R, et al. Anti-idiotype vaccine in colorectal cancer patients. Hybridoma 1993; 12: 515-520.
33. Mittelman A, Puccio C, Chun H, et al. Humoral antimelanoma immunity: induction by mouse antiidiotypic mAb, MK2-23 and association with survival of patients with advanced melanoma. Mt Sinai J Med 1992; 59: 234-237.
34. Schlebusch H, Wagner U, Grünn U, et al. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 1995; 14: 167-174.
35. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125: 373-389.
36. Wagner U, Köhler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001; 7: 1154-1162.
37. Reinartz S, Köhler S, Scheleusch H, et al. Vaccination of patients with advanced ivarian cercinoma with the ant-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004; 10: 1580-1587.
38. Pfisterer J, du Bois A, Sehouli J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006; 17: 1568-1577.
39. Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006; 12: 5503-5510.
40. Pfisterer J, Berek JS, Casado A, et al. Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) trial. J Clin Oncol 2011; (suppl) abstr LBA5002.
41. Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5: 1331-1338.
42. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-3108.
43. Hernando JJ, Park TW, Kübler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002; 51: 45-52.
44. Apostolopoulos V, Barnes N, Pietersz GA, et al. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000; 18: 3174-3184.
45. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12: 869-877.
46. Hernando JJ, Park TW, Fischer HP, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007; 8: 451-454.
47. Peoples GE, Anderson BW, Lee TV, et al. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 1999; 5: 4214-4223.
48. Marijt E, Wafelman A, van der Hoorn M, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica 2007; 92: 72-80.
49. Toh U, Yamana H, Sueyoshi S, et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000; 6: 4663-4673.
50. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-5239.
51. Steis RG, Urba WJ, VanderMolen LA, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 1990; 8: 1618-1629.
52. Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990; 50: 6302-6310.
53. Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 1994; 16: 198-210.
54. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87: 1463-1469.
55. Canevari S, Mezzanzanica D, Mazzoni A, et al. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 1995; 4: 423-427.
56. Canevari S, Ménard S, Mezzanzanica D, et al. Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells. Int J Cancer Suppl 1998; 2: 18-21.
57. Bolhuis RL, Lamers CH, Goey SH, et al. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl 1992; 7: 78-81.
58. Lamers CH, Gratama JW, Warnaar SO, et al. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer 1995; 60: 450-457.
59. Lum LG, LeFever AV, Treisman JS, et al. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J Immunother 2001; 24: 408-419.
60. June CH, Ledbetter JA, Linsley PS, et al. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11: 211-216.
61. Jenkins MK, Johnson JG. Molecules involved in T-cell costimulation. Curr Opin Immunol 1993; 5: 361-367.
62. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997; 159: 5921-5930.
63. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989; 86: 1333-1337.
64. Tibben JG, Boerman OC, Massuger LF, et al. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer 1996; 66: 477-483.
65. Wright SE, Kilinski L, Talib S, et al. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother 2000; 23: 2-10.
66. Ioannides CG, Fisk B, Jerome KR, et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993; 151: 3693-3703.
67. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 2012; 35: 196-204.
68. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest 2008; 37: 215-225.
69. Alajez NM, Schmielau J, Alter MD, et al. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 2005; 105: 4583-4589.
70. Napoletano C, Bellati F, Tarquini E, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008; 198: 99.e1-e7.
71. Frazer IH, Thomas R, Zhou J, et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 1999; 168: 131-142.
72. Soto U, Das BC, Lengert M, et al. Conversion of HPV 18 positive non-tumorigenic HeLafibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 1999; 18: 3187-3198.
73. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999; 259: 305-313.
74. Barnard P, Payne E, McMillan NA, et al. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 2000; 277: 411-419.
75. Sheu BC, Chiou SH, Chang WC, et al. Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clin Immunol 2005; 115: 295-301.
76. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-1527.
77. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4: 2103-2109.
78. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptide. J Immunol 2001; 69: 350-358.
79. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papilomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14: 169-177.
80. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14: 178-187.
81. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6: 3406-3416.
82. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein- based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004; 53: 642-650.
83. Frazer IH, Quinn M, Nicklin JL, et al. Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIXTM adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23: 172-181.
84. Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007; 121: 2794-2800.
85. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-442.
86. Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein- based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106: 453-460.
87. Roman LD, Wilczynski S, Muderspach LI, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007; 106: 558-566.
88. Sheets EE, Urban RG, Crum CP, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003; 188: 916-926.
89. Brun JL, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011; 204: 169.e1-e8.
90. Santin AD, Bellone S, Gokden M, et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002; 346: 1752-1753.
91. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129: 521-530.
92. Santin AD, Bellone S, Palmieri M, et al. cHPV 16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006; 100: 469-478.
93. Santin AD, Bellone S, Palmieri M. et al. Human Papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008; 82: 1968-1979.
94. Baldwin PJ, van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003; 9: 5205-5213.
95. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032-6041.
96. Davidson EJ, Faulkner RL, Sehr P, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004; 22: 2722-2729.
97. Tsuda N, Mochizuki K, Harada M, et al. Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 60-72.
98. OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission. Available at: http://clinicaltrials.gov/ct2/show/NCT 00857545 [accessed September, 2012].
99. Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer. Available at: http://clinicaltrials.gov/ct2/sh ow/NCT00408590 [accessed September 30, 2012].
100. Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00602277 [accessed September 30, 2012].
101. Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod. Available at: http://clinicaltrials.gov/ct2/show/NCT00799110 [accessed September 30, 2012].
102. Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine. Available at: http://clinicaltrials.gov/ct2/show/NCT00228358 [accessed September 30, 2012].
103. Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00660101 [accessed September 30, 2012].
104. Markman M, Brady M, Hutson A, et al. Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Cancer 2009; 19: 223-9.
105. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
106. Food and Drug Administration. Summary review - summary basis for regulatory action: sipuleucel-T (Provenge). April 29, 2010. (http://www.fda.gov/downloads/BiologicsBlood Vaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM213114.pdf.).
107. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010; 363: 411-422.
108. Leffers N, Daemen T, Helfrich W, et al. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 2010; 1: CD007287.